Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Bioasis","sponsor":"CHIESI USA INC","pharmaFlowCategory":"D","amount":"$141.0 million","upfrontCash":"$3.0 million","newsHeadline":"Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Peptide","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed"},{"orgOrder":0,"company":"Bioasis","sponsor":"Oxyrane","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioasis Technologies Inc. and Oxyrane UK Ltd. enter into a Research Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"Bioasis","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioasis Enters Into Research Collaboration With Janssen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Bioasis","sponsor":"Neuramedy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioasis and Neuramedy Enter into Research Collaboration and License Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"Bioasis","sponsor":"Cresence","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling"},{"orgOrder":0,"company":"Bioasis","sponsor":"Midatech Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"Undisclosed","date":"January 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Bioasis

    Menu

    Bioasis

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Bioasis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc

              Details:

              Bioasis Technologies is developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (CNS) disorders.

              Lead Product(s): Undisclosed

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Peptide

              Partner/Sponsor/Collaborator: Midatech Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Termination January 23, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Bioasis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets

              Details:

              Under the terms of the agreement, the Company purchased all right, title and interest in the intellectual property owned by the Sellers related to their epidermal growth factor (EGF) platform, including CRES101.

              Lead Product(s): CRES101

              Therapeutic Area: Rare Diseases and Disorders Product Name: CRES101

              Highest Development Status: IND Enabling Product Type: Large molecule

              Recipient: Cresence

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition June 16, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Bioasis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bioasis and Neuramedy Enter into Research Collaboration and License Agreement

              Details:

              Under the terms of the agreement, Neuramedy has obtained worldwide rights to research, develop and commercialize an xB3TM version of its antibody, Tomaralimab, directed at the Toll-like receptor 2.

              Lead Product(s): Tomaralimab

              Therapeutic Area: Neurology Product Name: NM-101

              Highest Development Status: Preclinical Product Type: Large molecule

              Recipient: Neuramedy

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 10, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Bioasis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bioasis Enters Into Research Collaboration With Janssen

              Details:

              Under the terms of the agreement, Janssen will have the option to research, develop and commercialize novel products based on Bioasis’ xB3TM platform. The agreement was facilitated by Johnson & Johnson Innovation.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 11, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Bioasis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bioasis Technologies Inc. and Oxyrane UK Ltd. enter into a Research Collaboration

              Details:

              Oxyrane is developing enhanced enzyme replacement therapies (ERT) for lysosomal storage diseases (LSDs) using a proprietary, glyco-engineered yeast expression system for efficient targeting of enzymes to the lysosome.

              Lead Product(s): Enzyme Replacement Therapies

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Oxyrane

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration June 30, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Bioasis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance

              Details:

              The unique delivery method of their xB3 platform has the potential to overcome a significant challenge in the treatment of many neurological disorders, which is the ability to cross the blood brain barrier.

              Lead Product(s): Transcend-peptide

              Therapeutic Area: Genetic Disease Product Name: xB3

              Highest Development Status: Undisclosed Product Type: Peptide

              Partner/Sponsor/Collaborator: CHIESI USA INC

              Deal Size: $141.0 million Upfront Cash: $3.0 million

              Deal Type: Licensing Agreement June 29, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY